IL220937A0 - Therapies for treating hepatitis c virus infection - Google Patents
Therapies for treating hepatitis c virus infectionInfo
- Publication number
- IL220937A0 IL220937A0 IL220937A IL22093712A IL220937A0 IL 220937 A0 IL220937 A0 IL 220937A0 IL 220937 A IL220937 A IL 220937A IL 22093712 A IL22093712 A IL 22093712A IL 220937 A0 IL220937 A0 IL 220937A0
- Authority
- IL
- Israel
- Prior art keywords
- therapies
- virus infection
- treating hepatitis
- hepatitis
- treating
- Prior art date
Links
- 208000010710 hepatitis C virus infection Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29964310P | 2010-01-29 | 2010-01-29 | |
| US30850610P | 2010-02-26 | 2010-02-26 | |
| US30911710P | 2010-03-01 | 2010-03-01 | |
| US32439510P | 2010-04-15 | 2010-04-15 | |
| PCT/US2011/022854 WO2011094489A1 (en) | 2010-01-29 | 2011-01-28 | Therapies for treating hepatitis c virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL220937A0 true IL220937A0 (en) | 2012-09-24 |
Family
ID=43901208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL220937A IL220937A0 (en) | 2010-01-29 | 2012-07-12 | Therapies for treating hepatitis c virus infection |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130034522A1 (https=) |
| EP (1) | EP2528605A1 (https=) |
| JP (1) | JP2013518124A (https=) |
| KR (1) | KR20120139699A (https=) |
| CN (1) | CN102844030A (https=) |
| AU (1) | AU2011210795A1 (https=) |
| CA (1) | CA2788348A1 (https=) |
| IL (1) | IL220937A0 (https=) |
| MX (1) | MX2012008652A (https=) |
| RU (1) | RU2012136824A (https=) |
| SG (1) | SG182589A1 (https=) |
| TW (1) | TW201130502A (https=) |
| WO (1) | WO2011094489A1 (https=) |
| ZA (1) | ZA201205547B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| WO2012006060A1 (en) * | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
| DE202012012955U1 (de) * | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2170020C (en) | 1992-12-29 | 2005-08-02 | Dale J. Kempf | Retroviral protease inhibiting compounds |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
| EP0966465B1 (en) | 1997-03-14 | 2003-07-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
| AP1498A (en) | 1999-03-19 | 2005-11-21 | Vertex Pharma | Inhibitors of impdh enzyme. |
| WO2002000851A2 (en) | 2000-06-28 | 2002-01-03 | National Research Council Of Canada | Helicobacter dd-heptosyltransferase |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| US6881741B2 (en) | 2001-06-11 | 2005-04-19 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| WO2004013300A2 (en) | 2002-08-01 | 2004-02-12 | Pharmasset Inc. | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections |
| CA2413705A1 (en) | 2002-12-06 | 2004-06-06 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| BRPI0407587A (pt) | 2003-02-18 | 2006-02-14 | Pfizer | inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam |
| CA2516016C (en) | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| US6908901B2 (en) | 2003-03-05 | 2005-06-21 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor peptide analogs |
| CL2004001161A1 (es) | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| WO2005018330A1 (en) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| EP1670415A4 (en) | 2003-09-12 | 2007-12-05 | Vertex Pharma | ANIMAL MODEL FOR STUDYING PROTEASES ACTIVITY AND HEPATIC DISORDERS |
| US6933760B2 (en) | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
| ES2361997T3 (es) | 2003-09-22 | 2011-06-27 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos activos contra el virus de la hepatitis c. |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ATE495185T1 (de) | 2004-01-21 | 2011-01-15 | Boehringer Ingelheim Int | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
| CN102911161A (zh) | 2004-02-20 | 2013-02-06 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
| US20050288333A1 (en) | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
| TW201424733A (zh) * | 2004-10-29 | 2014-07-01 | Vertex Pharma | 劑量型式 |
| EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| EP1993994A2 (en) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| WO2007109605A2 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| CA2645566A1 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| JP5290186B2 (ja) * | 2006-11-15 | 2013-09-18 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染症の治療または予防用のチオフェン類似体 |
| MX2009006806A (es) | 2006-12-22 | 2009-08-27 | Vertex Pharma | Secado por rocio fluidizado. |
| DK2114924T3 (da) | 2007-02-27 | 2012-04-10 | Vertex Pharma | Co-krystaller og farmaceutiske sammensætninger omfattende disse |
| JP2010528013A (ja) | 2007-05-21 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
| CA2691444C (en) * | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| WO2010002998A1 (en) * | 2008-07-03 | 2010-01-07 | Gilead Sciences, Inc. | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
-
2011
- 2011-01-28 RU RU2012136824/15A patent/RU2012136824A/ru not_active Application Discontinuation
- 2011-01-28 CN CN2011800168308A patent/CN102844030A/zh active Pending
- 2011-01-28 KR KR1020127021714A patent/KR20120139699A/ko not_active Withdrawn
- 2011-01-28 CA CA2788348A patent/CA2788348A1/en not_active Abandoned
- 2011-01-28 WO PCT/US2011/022854 patent/WO2011094489A1/en not_active Ceased
- 2011-01-28 SG SG2012053120A patent/SG182589A1/en unknown
- 2011-01-28 AU AU2011210795A patent/AU2011210795A1/en not_active Abandoned
- 2011-01-28 MX MX2012008652A patent/MX2012008652A/es active IP Right Grant
- 2011-01-28 EP EP11703776A patent/EP2528605A1/en not_active Withdrawn
- 2011-01-28 TW TW100103512A patent/TW201130502A/zh unknown
- 2011-01-28 JP JP2012551302A patent/JP2013518124A/ja active Pending
-
2012
- 2012-07-12 IL IL220937A patent/IL220937A0/en unknown
- 2012-07-23 ZA ZA2012/05547A patent/ZA201205547B/en unknown
- 2012-07-27 US US13/559,995 patent/US20130034522A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120139699A (ko) | 2012-12-27 |
| WO2011094489A1 (en) | 2011-08-04 |
| TW201130502A (en) | 2011-09-16 |
| JP2013518124A (ja) | 2013-05-20 |
| AU2011210795A1 (en) | 2012-08-02 |
| US20130034522A1 (en) | 2013-02-07 |
| RU2012136824A (ru) | 2014-03-10 |
| MX2012008652A (es) | 2012-08-23 |
| ZA201205547B (en) | 2013-04-24 |
| EP2528605A1 (en) | 2012-12-05 |
| CN102844030A (zh) | 2012-12-26 |
| CA2788348A1 (en) | 2011-08-04 |
| SG182589A1 (en) | 2012-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201205547B (en) | Therapies for treating hepatitis c virus infection | |
| ZA201404061B (en) | Compositions and methods for treating the hepatitis c virus | |
| IL221033A0 (en) | Hepatitis c virus inhibitors | |
| EP2575819A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
| IL245348A0 (en) | Compounds for the treatment of paramyxoviridae virus infections | |
| IL224298A (en) | Hepatitis virus inhibitors c | |
| ZA201306720B (en) | Hepatitis c virus inhibitors | |
| EP2603080A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| IL229270B (en) | Hepatitis c virus inhibitors | |
| SG2014010490A (en) | Combination treatments for hepatitis c | |
| EP2768517A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| ZA201404494B (en) | Method for treating hepatitis c virus infection using quercetin-containing compositions | |
| ZA201309356B (en) | Hepatitis c virus inhibitors | |
| PL2534150T3 (pl) | Sposoby leczenia infekcji wirusowej | |
| ZA201401020B (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| ZA201300992B (en) | Combination therapy for treating hcv infection | |
| ZA201503458B (en) | Hepatitis c virus inhibitors | |
| ZA201307019B (en) | Compositions for preventing and/or treating and infection by an hiv-1 virus | |
| EP2826486A4 (en) | PRODUCT FOR TREATING VIRAL HEPATITIS C | |
| IL228725A0 (en) | Treatment of hepatitis c virus infection with alisporir | |
| IL232889A0 (en) | Compounds and methods for treating hepatitis c virus | |
| HK1190604A (en) | Treatment of hepatitis c virus infection with alisporivir | |
| ZA201306878B (en) | Treatment of hepatitis c virus infection with alisporivir | |
| AU2012905097A0 (en) | Agents and methods for inhibiting virus infection | |
| EP2589595A4 (en) | MEANS FOR THE TREATMENT OF HCV INFECTIONS |